Adma Biologics (ADMA) FY2021 results: revenue $81 million, up 91.7% on the year
Adma Biologics, Inc. (ADMA) reported revenue of $81 million for fiscal 2021, the year ended 31 December 2021, up 91.7% on the year before. Net income was -$72 million, and diluted earnings per share $-0.51. The figures are the company's own, from the 10-K it filed with the SEC on 24 March 2022.
Revenue
$81 million
+91.7% on the year
FY2014FY2021
Operating margin
-72.1%
-153.8% a year earlier
FY2014FY2021
Net income
-$72 million
FY2014FY2021
Diluted EPS
-$0.51
FY2014FY2021
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Operating cash flow
-112
-102
-76.2
Capital expenditure
13.5
12.7
3.8
+6.2%
Free cash flow
-126
-115
-80.0
Free cash flow margin
-155.5%
-271.7%
-272.6%
Cash from investing
-13.5
-12.7
-3.8
Cash from financing
121
144
80.0
-15.9%
Depreciation and amortisation
4.8
3.2
2.4
+50.0%
Share-based compensation
3.5
2.9
2.7
+22.2%
Diluted shares, weighted
140m
86m
n/a
+62.0%
Shares outstanding at period end
196m
105m
59m
+86.7%
Balance sheet
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Shareholders' equity
141
88.2
26.2
+60.0%
Debt
94.9
93.0
83.2
+2.0%
Operating lease liabilities
7.5
4.3
n/a
+72.2%
Other liabilities
32.8
22.1
17.7
+48.1%
Total liabilities and equity
276
208
127
+33.0%
Fixed assets
50.9
41.6
31.7
+22.5%
Goodwill
3.5
3.5
3.5
0.0%
Intangible assets
1.7
2.4
3.2
-29.3%
Cash and equivalents
51.1
55.9
26.8
-8.6%
Receivables
28.6
13.2
3.5
+115.9%
Inventory
125
81.5
53.1
+53.0%
Other assets
15.7
9.4
5.4
+66.5%
Total assets
276
208
127
+33.0%
10-K for the year ended 31 December 2021, filed 24 March 2022: the filing.